<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780052</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 04701</org_study_id>
    <nct_id>NCT00780052</nct_id>
  </id_info>
  <brief_title>Infusional C-myb ASODN in Advanced Hematologic Malignancies</brief_title>
  <acronym>UPCC 04701</acronym>
  <official_title>Infusional C-myb Antisense Oligodeoxynucleotide in Advanced Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether C-myb Antisense (AS) Oligonucleotides&#xD;
      (ODNs)is a possible treatment modality for advanced hematologic malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities and maximum tolerated dose and maximum tolerated duration of c-myb AS ODN</measure>
    <time_frame>At study completion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>c-myb AS ODN as a 24-hour continuous infusion over 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>c-myb AS ODN</intervention_name>
    <description>Subjects will be admitted to the hospital to receive c-myb AS ODN as a 24-hour continuous intravenous infusion over 7 days. Dose level is increased with each new subject to determine if there is a MTD.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have one of the following: acute myeloid or lymphoid leukemia; or&#xD;
             Myeloproliferative disorder(MPD) including Chronic Myelogenous Leukemia (CML); or&#xD;
             Myelodysplastic Syndrome (MDS); or Non-Hodgkin's Lymphoma (including CLL); or Multiple&#xD;
             Myeloma&#xD;
&#xD;
          -  Patients with acute leukemia must meet one of the following conditions:&#xD;
&#xD;
             *have disease which is refractory to a course of standard induction chemotherapy *have&#xD;
             relapsed diseased after documentation of previous clinical remission or *have&#xD;
             untreated disease and not be a candidate for conventional first line treatment&#xD;
&#xD;
          -  Patients with CML or other MPD must have evidence of accelerated phase or blast crisis&#xD;
&#xD;
          -  Patients having clinical features of CML in transformation but who are negative for&#xD;
             Philadelphia chromosome may be entered provided there is a prior definable chronic&#xD;
             phase&#xD;
&#xD;
          -  Patients with Philadelphia chromosome positive CML must have failed treated with&#xD;
             Gleevec (Imatinib) in order to be eligible for study&#xD;
&#xD;
          -  Patients with myelodysplastic syndrome (MDS) must have &gt; 5% blasts in the peripheral&#xD;
             blood or bone marrow and have at diagnosis as IPSS score of &gt;= 1&#xD;
&#xD;
          -  Patients with CLL must have relapsed or refractory disease after at least three&#xD;
             courses of conventional therapy and have been determined to no longer be a candidate&#xD;
             for conventional therapy&#xD;
&#xD;
          -  Patients with non-Hodgkin's lymphoma (other than CLL) must have relapsed or refractory&#xD;
             disease after at least two courses of chemotherapy and have been determined not to be&#xD;
             a candidate for further conventional therapies&#xD;
&#xD;
          -  Patients with multiple myeloma must have failed at least 3 prior therapies&#xD;
&#xD;
          -  Performance Status 0, 1 or 2&#xD;
&#xD;
          -  Serum creatinine &lt; 2.0 mg/dl; serum bilirubin &lt; 2 mg/dl and AST/ALT &lt; 3.0 x upper&#xD;
             limit of normal&#xD;
&#xD;
          -  PTT within normal range&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Patients must have an indwelling central venous catheter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant cardiac disease which requires active therapy&#xD;
&#xD;
          -  Intercurrent organ damage or medical problems that will jeopardize outcome of therapy&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Received prior c-myb AS ODN therapy&#xD;
&#xD;
          -  Patients with suitable HLA identical sibling donor who are deemed to be appropriate&#xD;
             and willing candidates for allogeneic bone marrow transplantation&#xD;
&#xD;
          -  Patients requiring anticoagulation with unfractionated heparin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selina Luger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania Abramson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>October 24, 2008</study_first_submitted>
  <study_first_submitted_qc>October 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2008</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>c-myb</keyword>
  <keyword>c-myb AS ODN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

